Rhabdomyolysis is characterized by a marked elevation of the creatine kinase (CK) levels and myoglobinuria, thus leading to renal dysfunction. Various viruses or bacteria can be etiologic agents, but mycosis has only rarely been reported to be a cause of rhabdomyolysis. In this report, we describe an adolescent male with acute myeloid leukemia who underwent allogeneic bone marrow transplantation and thereafter developed rhabdomyolysis and Candida parapsilosis fungemia almost at the same time. Following treatment for C. parapsilosis, the transaminase and CK levels both satisfactorily decreased. This case illustrates that C. parapsilosis infection may be a causative agent of rhabdomyolysis in immunocompromised patients.
Introduction
Rhabdomyolysis is characterized by a marked elevation of the creatine kinase (CK) levels and myoglobinuria, thus leading to renal dysfunction. Patients with rhabdomyolysis usually feel muscle stiffness and tenderness, and often suffer from life-threatening complications, such as acute kidney injury, compartment syndrome, and severe electrolyte disorders due to muscle damage. Conversely, some patients may not demonstrate any physical symptoms, except for some abnormal laboratory findings (1) .
Rhabdomyolysis can be caused by various factors, with the etiologies categorized as traumatic (crush injury or surgery), non-traumatic exertional (extreme exertion, metabolic myopathies, or hyperthermia), and non-traumatic nonexertional (electrolyte abnormalities, drugs and toxins, or infections) (1) (2) (3) (4) . Rhabdomyolysis is also known to be induced by various viruses and bacteria (1, 5, 6) , whereas mycosis has only rarely been identified as a cause, with only two such cases previously reported in the English literature (7, 8) . We herein describe the first known case of rhabdomyolysis induced by sepsis due to Candida parapsilosis.
Case Report
A 21-year-old man was diagnosed with acute myeloid leukemia (AML) with inv(16)(p13.1q22), according to the World Health Organization classification. After two courses of induction therapy, he achieved a hematologic complete remission (CR). He then underwent four courses of consolidation therapy; allogeneic bone marrow transplantation (BMT) was planned because of the initial induction failure. He underwent BMT from a human leukocyte antigen mismatched (HLA-DRB1 locus mismatched), unrelated, male donor after myeloablative conditioning using total body irra- diation (3 Gy, days -7 to -4), and cyclophosphamide (60 mg/kg, days -3 to -2); tacrolimus and mycophenolate mofetil (MMF) were used for graft-versus-host disease (GVHD) prophylaxis. Initially, tacrolimus was continuously infused with a target blood concentration between 12 and 15 ng/mL. Neutrophil engraftment was achieved on day 11, with complete chimerism and molecular CR confirmed on day 30. He developed an itchy skin rash on day 6, and a skin biopsy performed on day 12 revealed no signs of acute GVHD; however, engraftment syndrome was suspected. We started to only use a steroid ointment, and his rash disappeared by day 35. MMF was tapered off from day 45 and was stopped on day 92. After switching to oral tacrolimus administration from day 85, the target trough level ranged between 7 and 10 ng/mL. He never developed acute or chronic GVHD. However, he could not be discharged because of severe anorexia; thus, he required total parenteral nutrition (TPN) via a central venous (CV) catheter.
On day 97, he was complicated with pharyngitis, and was successfully treated with piperacillin/tazobactam. At this time, the patient's serum CK transiently increased to 1,674 IU/L (normal range, 56-248 IU/L), but thereafter immediately decreased to 264 IU/L. This elevation was thought to be due to a difficult rehabilitation. On day 105, he had shaking chills, and his body temperature and heart rate suddenly increased to 40.5°C and 132/min, respectively. Except for these symptoms, he did not have any signs of septic shock. He complained of bilateral leg pain. We immediately removed his CV catheter, under a suspicion of a catheter infection, and we switched the piperacillin/tazobactam to cefepime. On day 107, his CK level was markedly elevated dL (normal range, 2.4-4.5 mg/dL); his creatinine level was 0.98 mg/dL (normal range, 0.5-1.3 mg/dL). His coagulation test was within the normal limits throughout these events. His urine was strongly positive for occult blood, but his urinary sediment contained few red blood cells, and the patient's urinary myoglobin level was elevated to 2,510.9 ng/ mL. From these results, we diagnosed him to have rhabdomyolysis with myoglobinuria. At that time, famotidine, teprenone, and fluconazole (200 mg/day) orally with cefepime intravenously were administered, except for TPN. On day 109, candidemia due to non-Candida albicans was detected from two of four blood culture bottles, which were obtained before switching to cefepime on day 105, but no bacteria were identified (Figure) , and no bacteria were detected from a CV catheter culture either. In previous chemotherapy, he had a history of liver dysfunction probably due to micafungin and an allergic reaction due to liposomal amphotericin B; therefore, we started voriconazole instead of fluconazole. Eventually, Candida parapsilosis was identified on day 112. Although the antifungal sensitivity was good for both fluconazole and voriconazole, we continued to use voriconazole. The patient's levels of CK and hepatic enzymes decreased dramatically after the removal of the CV catheter, and his clinical manifestation and laboratory findings (AST, ALT, and CK) improved satisfactorily. The patient's level of CK decreased to 218 IU/L, which was within the normal range on day 116. The other laboratory data were as follows: AST 57 IU/L, ALT 109 IU/L, LDH 344 IU/L, potassium 5.1 mEq/L, phosphorus 4.8 mg/dL, and creatinine 1.02 mg/dL. β-D-glucan was not elevated, and the candida antigen in the blood was negative throughout the patient's clinical course. As of day 1,087, he remains in hematological and molecular CR.
Discussion
This unusual case of rhabdomyolysis was associated with C. parapsilosis sepsis after BMT for AML. The etiologies of rhabdomyolysis can be categorized as traumatic (crush injury or surgery), non-traumatic exertional (extreme exertion, metabolic myopathies, or hyperthermia), and non-traumatic non-exertional (electrolyte abnormalities, drugs and toxins, or infections) (1) (2) (3) (4) . In this case, there were no traumatic or exertional mechanisms. Rhabdomyolysis can be caused by various factors and not always by a single factor. Among them, it is reported that infection accounts for 1-31% as a cause of rhabdomyolysis (4, 5) .
We believe that there were several pathogeneses for the occurrence of rhabdomyolysis in the present case. The main cause may have been candidemia due to a C. parapsilosis infection. As far as we know, only two case reports have so far described mycoses as suspected triggers of rhabdomyolysis; one case involved infection by Candida sp. and Aspergillus hyphae, while the other involved a C. krusei infection (7, 8) . The clinical and laboratory findings of those cases are summarized in Table. Similar to the present case, both patients had acute leukemia and suffered from severe sepsis while immunocompromised; the mycoses were confirmed by a blood culture or at autopsy. In the two previously published cases, candidemia occurred following CV catheter insertion, and proceeded to rhabdomyolysis. The peak CK levels were very high in all three of the reported cases, including the present case. The other organisms, such as various viruses and bacteria may be another cause. He had pharyngitis before rhabdomyolysis; thus, it is possible that viremia or bacteremia due to the other organisms can potentially provoke rhabdomyolysis. The fact that the blood culture revealed no organisms except for C. parapsilosis does not always rule out the possibilities of viremia or bacteremia.
The second reason contributing to the rhabdomyolysis in this case may be associated with our patient's hypophosphatemia. Hypophosphatemic patients who have received hyperalimentation, without phosphate supplementation, have been reported to be at risk for rhabdomyolysis (9) . In the present case, the patient's serum phosphate level was almost within the normal range, under hyperalimentation, until day 105. However, on day 107, it decreased to 1.6 mg/dL when the serum CK level rose markedly. We supplied phosphate (60 mEq/day), and the serum phosphate level recovered to 4.5 mg/dL by day 110. Therefore, hypophosphatemia may be another risk factor for rhabdomyolysis.
The third factor that may contribute to the development of rhabdomyolysis was the use of various drugs, such as statins, antipsychotics, antihistamines, and colchicine. However, since our patient did not take these drugs, except for famotidine, which was administered from induction chemotherapy, a drug trigger was unlikely. Although the level of tacrolimus was stable, tacrolimus with the prophylactic use of fluconazole may contribute to the onset of rhabdomyolysis because of drug-to-drug interactions.
The present patient was immunocompromised because he had just undergone BMT for AML and had taken tacrolimus. Invasive fungal infections, including candidemia, are often found in these immunocompromised patients. In the present case, C. parapsilosis provoked severe sepsis. This yeast is highly susceptible to fluconazole (level of susceptibility, 91-96%) and voriconazole (level of susceptibility, 95-98%) (10), whereas the minimal inhibitory concentrations of the echinocandins for C. parapsilosis are higher than those for other species (11) . Despite the prophylactic use of fluconazole, non-albicans candidemia due to C. parapsilosis was detected. In addition to CV catheter removal and the administration of cefepime, we changed the antifungal agent to voriconazole because due to suspected fluconazole-resistant candidemia. Thereafter, the patient's clinical manifestation and laboratory findings markedly improved. We believe that the immediate removal of CV catheters has the best impact on obtaining a good clinical course, and this should be considered in such cases. This is the first report describing C. parapsilosis fungemia as a potential causative agent for rhabdomyolysis. Severe fungemia may therefore cause rhabdomyolysis in immunocompromised patients.
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